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Abstract
Purpose In Alzheimer’s disease (AD), increased metabolism
of monoamines by monoamine oxidase type B (MAO-B)
leads to the production of toxic reactive oxygen species
(ROS), which are thought to contribute to disease pathogene-
sis. Inhibition of the MAO-B enzyme may restore brain levels
of monoaminergic neurotransmitters, reduce the formation of
toxic ROS and reduce neuroinflammation (reactive
astrocytosis), potentially leading to neuroprotection.
Sembragiline (also referred as RO4602522, RG1577 and
EVT 302 in previous communications) is a potent, selective
and reversible inhibitor of MAO-B developed as a potential
treatment for AD.
Methods This study assessed the relationship between plasma
concentration of sembragiline and brain MAO-B inhibition in
patients with AD and in healthy elderly control (EC) subjects.
Positron emission tomography (PET) scans using [11C]-L-dep-
renyl-D2 radiotracer were performed in ten patients with AD
and six EC subjects, who received sembragiline each day for
6–15 days.
Results At steady state, the relationship between sembragiline
plasma concentration and MAO-B inhibition resulted in an
Emax of ∼80–90 % across brain regions of interest and in an
EC50 of 1–2 ng/mL. Data in patients with AD and EC subjects
showed that near-maximal inhibition of brain MAO-B was
achieved with 1 mg sembragiline daily, regardless of the pop-
ulation, whereas lower doses resulted in lower and variable
brain MAO-B inhibition.
Conclusions This PETstudy confirmed that daily treatment of
at least 1 mg sembragiline resulted in near-maximal inhibition
of brain MAO-B enzyme in patients with AD.
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Introduction
Expression of brain monoamine oxidase type B (MAO-B)
increases with age in healthy subjects [1, 2], and is further
increased in patients with Alzheimer’s disease (AD) [3, 4].
The brain areas with the greatest increase of MAO-B in pa-
tients with AD, ranging from 40 to 60 %, are also known to
contain high densities of senile plaques and tangles (temporal
and parietal cortices and hippocampus) [5]. Moreover, immu-
nohistochemical and autoradiographic studies in AD post-
mortem brain tissue have shown that MAO-B is highly
expressed in reactive astrocytes (gliosis) surrounding amyloid
plaques [6].
This up-regulation of MAO-B appears from an early stage,
and the increased activity is maintained throughout the course
of the disease [7], suggesting that MAO-B may contribute to
neurodegenerative processes by increasing oxidative stress in
at least two ways. Deamination of dopamine and other amines
by MAO-B leads to the formation of hydrogen peroxide that,
in the presence of trace amounts of metals, can be converted
into highly toxic hydroxyl radicals. Such radicals react avidly
with polyunsaturated fats in neuronal membranes, initiating
lipid peroxidation and cell death [8]. Secondly, increases in
MAO-B may also contribute to the reduced neurotransmitter
levels in the brains of AD patients which may lead to the
neuropsychological symptoms that are common in AD [6].
In humans, MAO-B preferentially deaminates dopamine
and phenylethylamine and has been suggested to participate
in the catabolism of noradrenaline [8]. In addition, MAO-B is
highly expressed in serotonin-containing neurons such as
those in the raphe nucleus. Dopamine and serotonin [9] levels
are reported to be decreased in the brains of individuals with
AD [10]. Thus, inhibition of MAO-B enzymatic activity is
expected to produce beneficial effects in AD by a dual mech-
anism, namely, by reducing neurodegenerative processes due
to oxidative stress and by re-establishing a physiological tonus
of monoaminergic neurotransmission.
Additional evidence for the efficacy of MAO-B inhibitors
(MAO-Bis) in the treatment of AD comes from clinical trials
with the MAO-Bi selegiline. The results of a 2-year trial in
patients with moderate AD suggest that selegiline may delay
functional deterioration and disease progression [11]. In addi-
tion, lazabemide, a selective MAO-Bi developed by Roche
but not continued due to hepatotoxic liability, showed a sig-
nificant improvement in cognition and functionality in pa-
tients with AD at doses previously shown in a positron emis-
sion tomography (PET) study with healthy volunteers to pro-
vide full blockade of the enzyme [12].
Sembragiline is a potent, selective and slowly reversible
MAO-Bi that has a novel chemical structure different from
that of lazabemide and selegiline. Based on MAO enzymatic
activity and displacement assays, the observed IC50 value
from in vitro affinity assays of the MAO-B enzyme is 5–6
nM [13]. This is approximately 600-fold more potent in
inhibiting MAO-B than MAO-A, and can thus achieve com-
plete MAO-B inhibition without affecting the activity of
MAO-A, as well as a wide variety of receptors, ion channels
or other enzymes.
Approximately 1040 subjects have participated in phase 1
and 2 sembragiline studies for smoking cessation and moder-
ate AD dementia [14]. In these studies, sembragiline was
found to be safe and well tolerated. At low doses, the pharma-
cokinetics (PK) of sembragiline are less than dose-proportion-
al, but after administration of approximately 5 mg of
sembragiline, the PK become linear, dose-proportional and
time-invariant, due to saturation of capacity-limited binding
to the peripheral enzyme receptor. In steady-state conditions,
sembragiline is slowly eliminated from the plasma, with a
terminal half-life of about 50–65 h in elderly subjects.
PET imaging studies in healthy young men confirmed that
sembragiline crosses the blood–brain barrier and inhibits brain
MAO-B enzyme activity. A dose-related increase in brain
MAO-B inhibition was demonstrated in young healthy sub-
jects who received single doses of 5 and 15 mg sembragiline.
Doses of 5 mg sembragiline, administered daily for 2–10
days, resulted in 52–78 % and 73–87 % inhibition in cortical
and subcortical regions, respectively (Roche data on file). At a
dose of 15 mg sembragiline, 68–74% and 83–86% inhibition
of brain MAO-B was observed in cortical and subcortical
regions, respectively; selegiline 20 mg, which was used as
active comparator in the study, provided mean inhibition
levels of 46–79 % for the different brain regions. Based on
simulations with a population PK–enzyme inhibition model
developed with data from 36 young healthy volunteers, a daily
dose of 1 mg sembragiline is anticipated to reach near full
MAO-B inhibition in most patients with AD, assuming no
relevant age or disease effect on the PK–MAO-B inhibition
relationship (Roche data on file).
The present repeated-dose PET study was undertaken to
confirm near-completeMAO-B enzyme inhibition in the brain
at the doses tested in a phase 2 clinical trial in patients with
modera t e AD, reg i s t e r ed a t C l in i ca lTr i a l s .gov
(NCT01677754). The objectives of this PET study were to
determine the effects of varying multiple oral doses of
sembragiline at steady state on brain MAO-B enzyme activity
in patients with mild-to-moderate AD using PET imagingwith
[11C]-L-deprenyl-D2, and to characterise the sembragiline
plasma–brain MAO-B inhibition relationship in patients with
AD compared to healthy age-matched controls.
Material and methods
The study was approved by the Regional Ethical Review
Board in Stockholm, Sweden, the Radiation Safety
Committee at the Karolinska University Hospital in Solna
Eur J Nucl Med Mol Imaging (2017) 44:382–391 383
(Stockholm, Sweden) and the Medical Product Agency in
Sweden. Patients with AD and healthy elderly controls (EC)
were enroled in Karolinska Hospital at Huddinge, Sweden.
Study design
In this multicentre, open-label, parallel-group, multiple-dose
study, sembragiline was administered orally once daily for 6–
15 days, depending on the dose group, to reach PK and en-
zyme inhibition steady-state conditions, and to allow for flex-
ibility in PET scan scheduling. The first dose was adminis-
tered at the study centre under the supervision of study per-
sonnel. On subsequent study days, treatment compliance was
assured by intake logs and tablet counting.
At baseline, each subject underwent a PET scan using
[11C]-L-deprenyl-D2 to measure MAO-B enzyme activity in
the brain prior to their first dose of allocated medication. The
second scan was performed at trough concentrations at steady
state prior to the last drug administration. Before each scan, a
cannula was inserted into a radial artery and another into an
antecubital vein. A sterile phosphate buffer (pH = 7.4) con-
taining radioligand was injected as a bolus over several sec-
onds into the cubital vein.
Subjects: inclusion, exclusion criteria
Healthy EC subjects with no evidence of AD or other cogni-
tive impairment and patients with AD aged 50–80 years were
enroled in the study. Informed consent was obtained from all
EC subjects and patients with AD, co-signed by the patient’s
closest relative and, for patients who were incapable of giving
informed consent, a legally authorised representative.
Patients with probable AD based on the National Institute
of Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders
Association (NINCDS/ADRDA) and the Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition (DSM-
IV) criteria, having a Mini-Mental State Exam (MMSE) score
of 17–26 inclusive, and a modified Hachinski Ischemia Scale
score ≤4 were enroled in the study. A neuroimaging evalua-
tion of the brain by magnetic resonance imaging (MRI) sup-
ported the diagnosis of AD, with no evidence of focal disease
to account for dementia or MRI exclusion criteria.
Background AD therapy of anticholinesterase inhibitors
(donepezil, galantamine, rivastigmine), antidepressants
(citalopram, paroxetine, sertraline), antipsychotics (risperi-
done, quetiapine), and memantine were permitted, provided
that they were maintained on a stable dosage regimen for at
least 1 month before day 1 of the study. Further benzodiaze-
pines with a short half-life (e.g. lorazepam), zolpidem,
zopiclone, eszopiclone and trazodone for insomnia were
permitted in patients with AD. Occasional use of oxazepam
or lorazepam for anxiety due to MRI scan was permitted in all
subjects.
EC subjects showed no clinically relevant findings on
physical examination, vital signs, electrocardiography (ECG)
or routine laboratory tests, and no suspicion of cognitive im-
pairment or early dementia on the Rey Auditory Verbal
Learning Test, MMSE, copying a cube and cross shown on
paper, and drawing a time point on a clock. EC subjects were
excluded if they had a family history of AD in first- or second-
degree relatives <75 years of age. All subjects were instructed
to follow a low-tyramine diet.
Exclusion criteria for patients with AD and EC subjects
included prior exposure to ionising radiation or radioisotope
for research that would exceed the local yearly radiation dose
exposure, and implants or ferromagnetic foreign bodies that
would present a risk during MRI.
Study treatment
For dosing with target doses <1 mg, a loading dose of 5 mg
was administered on day 1 to saturate the capacity-limited
binding of sembragiline, allowing achievement of steady-
state levels (PK and pharmacodynamic [PD]) within 7–14
days of dosing.
Group 1 was composed of three patients with AD and three
EC subjects who received 1 mg sembragiline daily for
2 weeks. This dose regimen was expected to provide enzyme
inhibition levels in the range of 80 % averaged across brain
regions of interest (ROIs). A loading dose of 5 mg was to be
administered on day 1 of treatment, followed by daily admin-
istration of target doses for doses <1 mg.
Group 2 was composed of three patients with AD and three
EC subjects who received a loading dose of 5 mg on day 1 and
doses of 0.2 mg/day for the following 6 days. This dose reg-
imen was expected to provide enzyme inhibition levels in the
range of 60–70 % averaged across brain ROIs.
Group 3 was composed of two patients with AD who re-
ceived a dose of 5 mg of sembragiline in order to better char-
acterise the plateau of enzyme inhibition in patients with AD.
Group 4 was composed of two patients with AD who re-
ceived a 5-mg loading dose on day 1, followed by 0.1 mg of
sembragiline for 13–16 days, to explore enzyme inhibition in
lower concentration ranges. Male subjects were selected for
group 4 in order to reduce the gender imbalance between the
patients with AD and the EC subjects.
Safety assessments
The safety of sembragiline was assessed by monitoring vital
signs, laboratory tests and adverse events (AEs), and by
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evaluating the risk of suicide using the Columbia Suicide
Severity Rating Scale.
Synthesis/preparation of [11C]-L-deprenyl-D2
[11C]-L-deprenyl-D2 was prepared by N-methylation of the
desmethyl L-deprenyl-D2 precursor using [
11C]methyl triflate
at room temperature [15]. The radiochemical yield was 40–
50 %, and the radiochemical purity was >95 %. The entire
synthesis was performed using a completely automated com-
mercial radiochemistry module (Scansys PETchemistry mod-
ule; Scansys Laboratorieteknik, Denmark).
MRI
All subjects underwent MRI, performed on a 1.5-T Siemens
MAGNETOM Avanto scanner at Medicinsk Röntgen,
Odenplan, Stockholm, Sweden. T1-weighted MR images
were obtained for each individual and used for grey and white
matter segmentation and delineation of ROIs using the
Anatomical Automatic Labeling (AAL) template [16].
The MR image was segmented into grey and white matter,
and cerebrospinal fluid segments, using the SPM5 segmenta-
tion algorithm in MATLAB (Wellcome Trust Centre for
Neuroimaging, London, UK; The MathWorks, Inc., Natick,
MA, USA). ROIs encompassing the lateral frontal cortex,
medial frontal cortex, lateral temporal cortex, and lateral pari-
etal cortex, lateral occipital cortex, hippocampus, putamen,
thalamus, cerebellum and whole brain were drawn on the
co-registered MR image and mapped onto the PET images,
and time–activity curves were extracted.
PET scan procedures
A transmission scan was performed using three rotating 68Ge
rod sources. [11C]-L-Deprenyl-D2 was injected intravenously
as a bolus, and emission data were acquired over 63 min using
the ECAT EXACT high-resolution system (Siemens Medical
Solutions, Malvern, PA, USA). The injected radioactivity was
targeted to approximately 300 MBq. The injected mass of
deprenyl was to be ≤100 μg, and ≥50–100-fold lower than
the typical administered dose of 5–10 mg deprenyl to patients
with Parkinson’s disease. The framing was as follows: 9
frames x 10 s, 2 frames x 15 s, 3 frames x 20 s, 4 frames x
30 s, 4 frames x 60 s, 4 frames x 180 s, 7 frames x 360 s.
Images were reconstructed using the standard filtered back-
projection, with a 2-mmHanning filter, a zoom factor of 2.17,
and a 128 × 128 matrix, and were corrected for attenuation
and scatter [17]. A summation PET image was created for
each subject and PET session by averaging across all frames.
Time–activity curves were then extracted from selected ROIs.
Arterial blood sampling
Arterial blood samples were used for measurement of radio-
activity in whole blood and plasma, as well as to determine the
parent fraction of the radioligand, using a reversed-phase
high-performance liquid chromatography method
(Karolinska University Hospital, Solna, Stockholm,
Sweden). A catheter was inserted in the radial artery, and
arterial blood was collected continuously for 10 min using
an automated blood sampling system at a speed of 5 mL/
min. Discrete blood samples were drawn approximately 10,
15, 20, 30, 45 and 60 min after each injection of [11C]-L-
deprenyl-D2.
Quantitation of [11C]-L-deprenyl-D2 binding
Time–activity data were analysed as previously described [18,
19]. Briefly, [11C]-L-deprenyl-D2 was quantified by the two-
tissue compartment model with three rate constants (K1, k2, k3)
using the PMOD 3.3 software package (PMOD Group,
Zurich, Switzerland), where the tissue compartments repre-
sent the free plus non-specifically bound and specifically
bound radiotracer. The outcome measure λk3 was calculated
as (K1/k2)*k3, using a non-linear approach, and was used as an
estimate for specific binding to MAO-B that was independent
of perfusion. The parameter λk3 (where λ =K1/k2) was used
as an estimate for specific binding to MAO-B, as it was found
to reflect the regional enzyme concentration more accurately
than k3 alone [19]. This is because λk3 is independent of
perfusion and has better reproducibility than k3 alone [20].
Inhibition of MAO-B in the brain by sembragiline from
regional λk3 was calculated as follows:






Here, Bdrug^ refers to scans after drug administration.
Assessment of PK
Blood samples were collected for sembragiline plasma con-
centrations and analysed with a validated liquid chromatogra-
phy–tandem mass spectrometry method (Covance Inc.,
Harrogate, North Yorkshire, UK). Plasma concentrations of
sembragiline were measured just prior to the second PETscan.
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Sembragiline plasma concentration–MAO-B enzyme
inhibition relationship
Pre-scan plasma concentrations were used for the analysis of
the relationship between MAO-B enzyme inhibition and
steady-state sembragiline plasma concentration, and were
characterised using a simple Emax model for each brain ROI:




,where Cp = 0 ng/mL at baseline and Cp = infinity (ng/mL) at
Emax; and where Cp is sembragiline plasma concentration (ng/
mL), Emax is maximum MAO-B enzyme inhibition (%) and
EC50 is sembragiline concentration (ng/mL) at half-maximal
inhibition.
The PK/PD analysis was performed using Phoenix
WinNonlin software version 6.2 (Pharsight Corporation,
Mountain View, CA, USA).
Results
Seventeen subjects (11 patients with AD and six EC subjects)
were enroled in the study. One enroled subject, a patient with
AD assigned to group 1, withdrew from the study because it
was not possible to perform arterial cannulation, and thus no
baseline PET scan was performed and no study treatment was
administered.
The demographics of the 16 patients who received
sembragiline are summarised in Supplementary Table 1.
Patients with ADwere on stable background AD therapy with
galantamine, donepezil, memantine, or a combination of gal-
antamine and memantine. All subjects were non-smokers.
There was an imbalance in gender between the patients with
AD and the healthy EC subjects. The majority (80 %) of
patients with AD were female, whereas the majority (83 %)
of EC subjects were male. Healthy control subjects
(70.5 years) were on average slightly older than the AD pa-
tients (65.0 years).
Table 1 Regional [11C]-L-deprenyl-D2 λk3 values before and after sembragiline treatment and respective occupancy values induced by the drug
regimens by population
Whole brain Hippocampus Striatum Thalamus Frontal cortex Parietal cortex
AD Baseline 0.18 (0.16–0.21) 0.24 (0.20–0.27) 0.30 (0.27–0.33) 0.28 (0.21–0.34) 0.17 (0.14–0.19) 0.17 (0.15–0.19)
0.1 mg Post-dose 0.08 (0.08–0.09) 0.11 (0.10–0.11) 0.12 (0.11–0.13) 0.11 (0.09–0.1) 0.07 (0.06–0.08) 0.07 (0.07–0.08)
N = 2 Occ, % 55.2 (52.5–57.9) 53.8 (49.2–58.4) 59.9 (58.3–61.6) 60.4 (56.7–64.1) 56.9 (54.8–59.0) 55.6 (53.4–57.7)
EC Baseline 0.16 (0.15–0.16) 0.23 (0.22–0.24) 0.27 (0.26–0.28) 0.25 (0.24–0.27) 0.15 (0.15–0.16) 0.15 (0.14–0.16)
0.2 mg Post-dose 0.08 (0.07–0.10) 0.11 (0.09–0.13) 0.12 (0.09–0.14) 0.12 (0.09–0.13) 0.07 (0.06–0.09) 0.07 (0.06–0.09)
N = 3 Occ, % 49.1 (37.5–58.8) 51.6 (42.3–60.9) 56.1 (47.9–66.3) 53.7 (44.5–66.6) 51.7 (41.9–63.5) 50.7 (37.2–62.3)
AD Baseline 0.20 (0.18–0.24) 0.31 (0.26–0.36) 0.35 (0.29–0.45) 0.31 (0.26–0.36) 0.21 (0.18–0.26) 0.20 (0.17–0.25)
0.2 mg Post-dose 0.06 (0.06–0.07) 0.07 (0.07–0.08) 0.08 (0.08–0.08) 0.07 (0.07–0.07) 0.06 (0.05–0.07) 0.06 (0.05–0.07)
N = 3 Occ, % 68.9 (64–75.2) 76.1 (70.7–81.1) 77.1 (72.5–83.3) 76.8 (71.7–80.6) 70.2 (60.4–79.4) 68.7 (57.1–79.3)
EC Baseline 0.19 (0.19–0.20) 0.28 (0.25–0.31) 0.35 (0.33–0.38) 0.32 (0.29─0.36) 0.18 (0.17─0.19) 0.18 (0.15–0.20)
1 mg Post-dose 0.05 (0.04–0.05) 0.04 (0.03–0.05) 0.05 (0.04–0.06) 0.05 (0.04–0.05) 0.04 (0.04–0.05) 0.04 (0.04–0.05)
N = 3 Occ, % 75.4 (73.2–79.2) 83.9 (79.7–87.6) 84.7 (81.3–87.6) 85.7 (82.9–88.2) 76.2 (72.7–79.3) 76.1 (71.3–79.9)
AD Baseline 0.16 (0.14–0.19) 0.22 (0.19–0.28) 0.28 (0.24–0.33) 0.25 (0.20–0.27) 0.16 (0.12–0.22) 0.16 (0.11–0.22)
1 mg Post-dose 0.04 (0.04–0.05) 0.05 (0.05–0.05) 0.04 (0.04–0.05) 0.04 (0.04–0.04) 0.04 (0.03–0.04) 0.04 (0.03–0.05)
N = 3, 2a Occ, % 75.5 (74.9–76.2) 79.2 (76.3–82.1) 85.0 (83.6–86.4) 86.0 (85.7–86.3) 79.7 (79.6–79.9) 78.0 (76.7–79.3)
AD Baseline 0.19 (0.18–0.19) 0.24 (0.24–0.24) 0.30 (0.29–0.31) 0.28 (0.21–0.34) 0.18 (0.16–0.19) 0.18 (0.17–0.19)
5 mg Post-dose 0.04 (0.04–0.05) 0.04 (0.03–0.05) 0.05 (0.04–0.05) 0.11 (0.09–0.12) 0.04 (0.04–0.04) 0.04 (0.03–0.04)
N = 2 Occ, % 76.3 (73.8–78.7) 83.3 (80.3–86.3) 84.8 (83.3–86.4) 86.3 (84.2–88.5) 77.8 (75.2–80.4) 78.1 (73.5–82.7)
AD Baseline 0.18 (0.14–0.24) 0.26 (0.19–0.36) 0.31 (0.24–0.45) 0.28 (0.20–0.36) 0.18 (0.12–0.26) 0.18 (0.11–0.25)
N = 10
EC Baseline 0.18 (0.15–0.20) 0.25 (0.22–0.31) 0.31 (0.26–0.48) 0.29 (0.24–0.36) 0.17 (0.15–0.19) 0.16 (0.14–0.20)
N = 10
Values are means (range)
Abbreviations: AD, patients with Alzheimer’s disease; EC, healthy elderly control; 0.1 mg, loading dose of 5 mg on day 1 followed by 0.1 mg q.d. for
days 2–15; 0.2 mg, loading dose of 5 mg on day 1 followed by 0.2 mg q.d. on days 2–7; 1 mg, 1 mg q.d. for 14 days; 5 mg, 5 mg q.d. for 6–9 days
a N = 3 for baseline λk3 values and N = 2 for post-dose λk3 and occupancy values
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Treatment compliance
All EC subjects documented daily drug intake and returned
the expected number of tablets. Two patients with AD each
missed one dose. Three patients with AD returned fewer tab-
lets than expected at the end of the study.
Safety
Sembragiline treatment was well tolerated in patients with AD
and EC subjects. No AE led to withdrawal from the study, and
all subjects completed their assigned treatment. In total, 11 of
20 AEs were reported as drug-related. Four of six EC subjects
experienced 13 AEs during the study, and seven AEs were
reported in three of ten patients with AD. Most AEs were of
mild intensity. There was no trend for increased AEs with dose
and no trend for body system-specific AEs. The most
frequently observed AE was diarrhoea, which occurred in
three subjects. There were no clinically significant changes
in laboratory parameters, vital signs or ECG measurements.
Sembragiline plasma concentrations
Mean plasma sembragiline concentrations taken prior to the
second PET scan and last dose administration are summarised
in Supplementary Table 2. With a loading dose of 5 mg
sembragiline for low doses (<1 mg) or multiple doses for
higher doses (≥1 mg), steady-state conditions were reached
within 14 days and at the time of the second PET scan.
Plasma concentrations at the time of PET scanning were in
the expected range, based on simulations with a population-
PK model previously developed in healthy volunteers (Roche
data on file). A trend toward higher exposure of sembragiline
in patients with AD (80% female) compared with EC subjects
Fig. 1 Visualization of MAO-B
inhibition in the brain following
treatment with 1 mg sembragiline
once a day for 2 weeks. Axial,
coronal and sagittal slices of
[11C]-L-deprenyl-D2 PET images
from a patient with AD in the 1-
mg group are presented before
and after sembragiline treatment
Eur J Nucl Med Mol Imaging (2017) 44:382–391 387
was suggested, where 83 % of enroled subjects were male. A
gender difference might explain the difference in PK between
the two populations.
Dosage of the [11C]-L-deprenyl-D2 tracer
The injected radioactivity and injected mass were 310 ±
35 MBq and 280 ± 37 MBq, and 0.28 ± 0.16 μg and 0.55 ±
0.60 μg, for EC subjects and AD patients, respectively.
A maximum injected mass of 5 μg was considered the
threshold, and injected doses were well below this value, en-
suring there was no effect on inhibition.
Injected radioactivity and total dose of the radiotracer per
treatment group, scan and population are listed in
Supplementary Table 3.
[11C]-L-Deprenyl-D2 binding in the brain
λk3 data representing specific binding of the [
11C]-L-deprenyl-
D2 tracer to MAO-B enzyme are summarised in Table 1. λk3
values before and after treatment are presented. Baseline λk3
values in patients with AD were similar to those observed in
healthy EC subjects. In both patients with AD and EC sub-
jects, baseline λk3 values were highest in the striatum and
lower in the cortical regions. Mean regional MAO-B inhibi-
tion levels induced by the different drug regimens are shown
in Table 1 and visualised in Figs. 1 and 2.
MAO-B inhibition at trough following 1 mg sembragiline
treatment was 75–86% (mean values) across all brain ROIs and
study populations, and was in the same range as that reported
with the 5-mg dose in this study (mean values: 76–86 %).
Doses of 0.1 mg and 0.2 mg were associated with lower and
highly variable levels of inhibition. Across all treatment groups,
the highest levels of inhibition were observed in subcortical
regions such as the hippocampus, thalamus and striatum.
Plots of pre-scan sembragiline concentration versus MAO-
B inhibition in steady-state conditions showed a sharp in-
crease at low plasma concentrations to a plateau in MAO-B
inhibition (Fig. 3). This was observed for both patients with
AD and EC subjects. The plateau occurred at plasma concen-
trations of 20–50 ng/mL.
At steady state, the sembragiline plasma concentration–in-
hibition relationship could be described by a simple Emax
model. Estimated Emax was 80–89 % and EC50 was 1–2 ng/
mL across ROIs and for both populations (Table 2).
Variability in PET data estimates was low to moderate, with
a coefficient of variation (CV) below 40 % for all parameters.
A population-PD model based on data from healthy volun-
teers and patients with AD yielded very similar Emax values,
predicting median enzyme inhibition of >80 % for doses
≥1 mg in the hippocampus 24 h post-last dose (Roche data
on file). Slightly lower EC50 values were estimated for pa-
tients with AD than for EC subjects.
Two patients with AD received concomitant sedative med-
ication on an as-needed basis; one received 5 mg oxazepam
and the other received 5 mg zopiclone. Data from these pa-
tients did not reveal any differences compared to other sub-
jects with regard to sembragiline plasma concentrations or
MAO-B inhibition. To the best of our knowledge, MAO-B
is not a known target of oxazepam or zopiclone.
Discussion
The purpose of the present imaging studywas to determine the
relationship between exposure to sembragiline and the
Fig. 2 Regional brain MAO-B
inhibition values (%) associated
with the various drug regimens.
Error bars represent standard
deviations. Abbreviations: AD,
patients with Alzheimer’s disease;
EC, healthy elderly control;
MAO-B, monoamine oxidase
type B
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inhibition of MAO-B enzyme activity in the brain after mul-
tiple oral doses in patients with AD. These data were used to
assist in dose selection of the phase 2 sembragiline study in
patients with moderate AD and in subsequent studies [21].
[11C]-L-Deprenyl-D2 was used to determine brain MAO-B
inhibition of sembragiline. Previous imaging studies were per-
formed with this radioligand for brain inhibition of MAO-Bis
in healthy subjects [22], in elderly subjects in and patients with
AD [23].
MAO-B inhibition following 1-mg treatment of
sembragiline was 75–86 % (mean values) across the six brain
ROIs (71–88 % overall) and study populations, and in the
same range as those reported for 5-mg doses, indicating that
plateau of inhibition had been reached at these doses. Doses of
0.1 and 0.2 mgwere associated with lower and highly variable
levels of inhibition. At a dose of 0.2 mg, women showed
higher MAO-B inhibition than men, which is consistent with
higher observed concentrations of sembragiline. However,
similar MAO-B inhibition between men and women was ob-
served after administration of a 1-mg dose, despite higher
sembragiline concentrations in women. This suggests that
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Fig. 3 Relationship between pre-scan plasma concentration of
sembragiline andMAO-B inhibition in patients with AD and EC subjects
in steady-state conditions following sembragiline treatment. (a)
hippocampus (b) striatum and (c) frontal cortex. Sembragiline was
administered once daily p.o. over 6–15 days at doses of between 0.1
and 5 mg. At doses of 0.1 mg and 0.2 mg, a loading dose of 5 mg of
sembragiline was administered. The arrows represent the range of pre-
scan concentrations at given sembragiline doses
Eur J Nucl Med Mol Imaging (2017) 44:382–391 389
population, around 1 mg might be needed, and could not be
achieved with lower doses (≤0.2 mg).
Across all treatment groups, a trend was observed for
higher levels of inhibition in subcortical regions such as the
hippocampus, thalamus and striatum than in cortical regions.
This is consistent with simulated median enzyme inhibition
with this compound based on population-PK model findings
in healthy young volunteers (Roche data on file), with other
MAO-Bi treatment in EC subjects [24], and with patients with
AD [23]. These trends might be explained by non-specific
binding of [11C]-L-deprenyl-D2, resulting in different binding
capacity at baseline, or by differences in K1, and may be re-
flective of MAO-B activity, as the binding capacity was
highest in the striatum and lower in the cortical regions in both
patients with AD and EC subjects in the present study as well
in others [23, 25].
In this study, baseline λk3 values in patients with AD were
similar to those observed in EC subjects, in contrast to previ-
ous reports where higher baseline [11C]-L-deprenyl-D2 bind-
ing was observed in patients with AD [3, 23]. However, the
present analysis is limited by the overall small sample size and
the slightly older EC population. When corrected for age, a
slight trend for higher λk3 in patients with AD was observed.
MAO-B is reduced and inhibited in smokers [26]; however, as
all subjects in this study were non-smokers, smoking status
was not a confounding factor in the comparison of the two
populations.
Concentration–enzyme inhibition relationship
The mean steady-state inhibition values were in the expected
range based on simulations with a preliminary PK enzyme
inhibition model. Plots of MAO-B inhibition versus concen-
tration showed a sharp increase at low concentrations, to a
plateau in MAO-B inhibition. The relationship between plas-
ma concentration and MAO-B inhibition could be well de-
scribed with an Emax model. The estimated EC50 of 1–2 ng/
mLwas comparable to the observed IC50 (5–6 nM) value from
in vitro affinity assays for the MAO-B enzyme (MAO enzy-
matic activity and displacement assays). PK/PD analysis per
study population yielded very similar Emax and EC50 values
for patients with AD and EC subjects. Slightly lower mean
EC50 values for the different ROIs were estimated for patients
with AD compared with EC subjects. However, this analysis
is limited by the small sample size, and this finding might be
explained by the variability in PK and inhibition data. These
data provide a good understanding of the concentration–en-
zyme inhibition relationship and assist in dose selection for
clinical efficacy studies. Regardless of the population,
sembragiline concentrations around 20 ng/mL might be need-
ed for near-complete MAO-B inhibition in the brain.
In conclusion, sembragiline treatment was well tolerated
and resulted in near-complete inhibition of the brain MAO-
B enzyme at 1 mg and 5 mg daily doses in patients with AD
and EC subjects. At these doses, near-maximal inhibition of
brain MAO-B was achieved regardless of the population. In
the phase 2 trial, sembragiline at 1 and 5mg daily failed on the
primary efficacy outcome on cognition (Alzheimer’s Disease
Assessment Scale–cognitive subscale (ADAS-Cog11) but
showed a trend toward an effect on functioning and potential
for an effect on neuropsychiatric symptoms compared with
placebo. The lack of a cognitive effect in moderate AD is
consistent with the effect of the MAO-B inhibitor, selegiline,
which showed no long-term benefit on cognition in patients
with moderate-to-severe AD [11]; rather, a treatment effect
has been observed only in 4–6- or 8–17-week studies [27].
The effects of sembragiline are also not in accord with the
results on cognition and functioning observed with the
MAO-B inhibitor lazabemide. Together, these studies suggest
that MAO-B inhibitors administered in addition to back-
ground therapy (i.e. acetylcholinesterase inhibitors,
memantine) in patients with moderate AD may not add to
the cognitive benefit.
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